Anti-NF-kB p65 Antibody (5J938) is a Mouse antibody targeting NF-kB p65. Anti-NF-kB p65 Antibody (5J938) can be used in WB,IHC-P,IHC-Fr,IF.

IgG1

5J938

Human,Mouse,Rat

1. 25 μg total protein per Lane of various lysates probed with NFKB p65 monoclonal antibody, unconjugated (TMAB-01227) at 1:2000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at RT for 60 min.
2. Paraformaldehyde-fixed, paraffin embedded Rat Spleen; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with NFKB p65 Monoclonal Antibody, Unconjugated (ascites of TMAB-01227) at 1:1500 overnight at 4°C, followed by conjugation to the secondary antibody and DAB staining.
3. Paraformaldehyde-fixed, paraffin embedded Human Spleen; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with NFKB p65 Monoclonal Antibody, Unconjugated (ascites of TMAB-01227) at 1:1500 overnight at 4°C, followed by conjugation to the secondary antibody and DAB staining.
4. Paraformaldehyde-fixed, paraffin embedded Human Colon Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with NFKB p65 Monoclonal Antibody, Unconjugated (ascites of TMAB-01227) at 1:1500 overnight at 4°C, followed by conjugation to the secondary antibody and DAB staining.
5. Paraformaldehyde-fixed, paraffin embedded Human Tonsil; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with NFKB p65 Monoclonal Antibody, Unconjugated (ascites of TMAB-01227) at 1:1500 overnight at 4°C, followed by conjugation to the secondary antibody and DAB staining.

WB: 1:500-2000; IHC-P: 1:200-1500; IHC-Fr: 1:200-1500; IF: 1:200-1500

Monoclonal

KLH conjugated synthetic peptide: human NFKB p65

Human

RELA

Transcription factor p65

RelA (p65),NFkB pathway,Inflammatory mediators,RelA (p65),NFkB pathway,Obesity,Host Immune Response,Host Virus Interaction,Alzheimer's disease,NFkB Pathway

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1.